Literature DB >> 30066360

FAS A-670G and Fas ligand IVS2nt A 124G polymorphisms are significantly increased in women with pre-eclampsia and may contribute to HELLP syndrome: a case-controlled study.

N Raguema1,2,3,4, H Zitouni1,2, M Ben Ali Gannoun1,2, D Benletaifa1,5, W Y Almawi6, T Mahjoub1, J L Lavoie3,4.   

Abstract

OBJECTIVE: We evaluated the association between the Fas-670A/G and the Fas ligand FasL IVS2nt 124 A/G polymorphisms and the risk of pre-eclampsia and its complications.
DESIGN: A case-controlled study.
SETTING: University Hospitals in most areas of Tunisia. POPULATION: We recruited 300 pregnant women who developed pre-eclampsia and 300 age-matched healthy pregnant women from the same hospital.
METHODS: Genotyping of Fas-670A/G and the FasL IVS2nt 124A/G gene polymorphisms were conducted using polymerase chain reaction-restriction fragment length polymorphism among our cohort. MAIN OUTCOME MEASURES: Fisher's exact test was used to compare the statistical differences between groups for categorical variables and Student t tests were used for continuous variables.
RESULTS: The frequency of the Fas-670G gene variant was significantly increased in women with pre-eclampsia (42%) compared with control women (30%; P < 0.001). Also, a statistically significant difference was obtained in the distribution of the FasL IVS2nt 124G gene variant when comparing women with pre-eclampsia (43%) with controls (30%; P < 0.001). Interestingly, we found that the carriage of Fas-670G was associated with increased liver enzymes, suggesting an increased prevalence of the haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome, a pre-eclampsia complication.
CONCLUSION: The Fas-670G and FasL IVS2nt 124G polymorphisms are associated with a higher risk of pre-eclampsia and its complications. TWEETABLE ABSTRACT: Polymorphisms in the Fas and FasL genes are associated with increased risk of pre-eclampsia and HELLP syndrome.
© 2018 Royal College of Obstetricians and Gynaecologists.

Entities:  

Keywords:  Fas; Fas ligand; haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome; hepatic enzyme levels; polymorphisms; pre-eclampsia

Mesh:

Substances:

Year:  2018        PMID: 30066360     DOI: 10.1111/1471-0528.15412

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  3 in total

1.  The role of FAS, FAS-L, BAX, and BCL-2 gene polymorphisms in determining susceptibility to unexplained recurrent pregnancy loss.

Authors:  Rafael Tomoya Michita; Francis Maria Báo Zambra; Lucas Rosa Fraga; Maria Teresa Sanseverino; Lavínia Schuler-Faccini; José Artur Bogo Chies; Priscila Vianna
Journal:  J Assist Reprod Genet       Date:  2019-04-02       Impact factor: 3.412

2.  Fas ligand neutralization attenuates hypertension, endothelin-1, and placental inflammation in an animal model of HELLP syndrome.

Authors:  Jacob Gibbens; Shauna-Kay Spencer; Lucia Solis; Teylor Bowles; Patrick B Kyle; Jamie L Szczepanski; John Polk Dumas; Reanna Robinson; Kedra Wallace
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-07-08       Impact factor: 3.619

3.  The relationship between Fas and Fas ligand gene polymorphism and preeclampsia risk.

Authors:  Tingting Wang; Yunyun Lian
Journal:  Biosci Rep       Date:  2019-02-15       Impact factor: 3.840

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.